Merck (MRK) Payables (2009 - 2026)
Merck (MRK) posted quarterly Payables of $6.0 billion for Q1 2026, up 2.47% year-over-year from $5.9 billion in Q1 2025, and down 8.22% quarter-over-quarter from $6.5 billion in Q4 2025.
Merck (MRK) Payables (2009 - 2026) Analysis & Trends
Merck (MRK) has reported Payables for 18 consecutive years, with $6.0 billion the latest figure, recorded in Q1 2026.
- In Q1 2026, Payables rose 2.47% year-over-year to $6.0 billion; the TTM figure through Mar 2026 stood at $6.0 billion (up 2.47% YoY), while the FY2025 annual figure was $6.5 billion, up 6.18% from the prior year.
- Payables eased to $6.0 billion in Q1 2026 per MRK's latest filing, from $6.5 billion in the prior quarter.
- Across five years, Payables topped out at $6.5 billion in Q4 2025 and bottomed at $5.1 billion in Q3 2022.
- Historically, Payables has averaged $5.7 billion across 5 years, with a median of $5.6 billion in 2023.
- Annual changes were most pronounced in 2022 — Payables dropped 5.56% — and 2025, when it gained 11.15%.
- Merck's Payables stood at $6.1 billion in 2022, then decreased by 3.92% to $5.9 billion in 2023, then gained by 4.33% to $6.2 billion in 2024, then grew by 6.18% to $6.5 billion in 2025, then dropped by 8.22% to $6.0 billion in 2026.
- Business Quant data shows MRK's Payables at $6.0 billion in Q1 2026, $6.5 billion in Q4 2025, and $6.2 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 653.86 Bn | 633.10 Bn | 17.26 Bn | 20.92 Bn |
| 2 | AbbVie | 470.11 Bn | 463.54 Bn | 12.70 Bn | 33.30 Bn |
| 3 | Merck | 375.28 Bn | 368.14 Bn | 12.21 Bn | 5.96 Bn |
| 4 | Novartis Ag | 302.83 Bn | 295.14 Bn | 11.24 Bn | 4.26 Bn |
| 5 | Astrazeneca | 257.33 Bn | 252.43 Bn | 12.86 Bn | 22.89 Bn |
| 6 | Amgen | 237.21 Bn | 223.22 Bn | 7.24 Bn | 2.87 Bn |
| 7 | Gilead Sciences | 183.09 Bn | 179.91 Bn | 6.22 Bn | 674.00 Mn |
| 8 | Pfizer | 160.08 Bn | 148.39 Bn | 10.94 Bn | 7.03 Bn |
| 9 | Gsk | 106.06 Bn | 101.89 Bn | 8.24 Bn | -25.00 Bn |
| 10 | Sanofi | 55.16 Bn | 47.78 Bn | 10.79 Bn | 8.31 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 5.96 Bn |
| Mar 31, 2026 | 6.01 Bn |
| Dec 31, 2025 | 6.54 Bn |
| Sep 30, 2025 | 6.19 Bn |
| Jun 30, 2025 | 5.95 Bn |
| Mar 31, 2025 | 5.86 Bn |
| Dec 31, 2024 | 6.16 Bn |
| Sep 30, 2024 | 5.57 Bn |
| Jun 30, 2024 | 5.50 Bn |
| Mar 31, 2024 | 5.52 Bn |
| Dec 31, 2023 | 5.91 Bn |
| Sep 30, 2023 | 5.39 Bn |
| Jun 30, 2023 | 5.32 Bn |
| Mar 31, 2023 | 5.59 Bn |
| Dec 31, 2022 | 6.15 Bn |
| Sep 30, 2022 | 5.14 Bn |
| Jun 30, 2022 | 5.25 Bn |
| Mar 31, 2022 | 5.49 Bn |
| Dec 31, 2021 | 6.38 Bn |
| Sep 30, 2021 | 5.03 Bn |